In addition, regorafenib significantly inhibited tumor growth, NF‐κB, p38, ERK activation and expression of tumor progression‐associated proteins in bladder cancer in vitro and in vivo. This evidence concerns the gene NFKB1 and urinary bladder carcinoma.